Your browser doesn't support javascript.
loading
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Seo, Ji-Min; Kang, Bobin; Song, Rina; Noh, Hanmi; Kim, Cheolmin; Kim, Jong-In; Kim, Minsoo; Ryu, Dong-Kyun; Lee, Min-Ho; Yang, Jeong-Sun; Kim, Kyung-Chang; Lee, Joo-Yeon; Lee, Hansaem; Woo, Hye-Min; Kim, Jun-Won; Choi, Jung-Ah; Song, Manki; Tomaszewska-Kiecana, Monika; Wolowik, Anna; Kulesza, Agnieszka; Kim, Sunghyun; Ahn, Keumyoung; Jung, Nahyun; Lee, Soo-Young.
Afiliación
  • Seo JM; Celltrion Inc, Incheon, Republic of Korea.
  • Kang B; Celltrion Inc, Incheon, Republic of Korea.
  • Song R; Celltrion Inc, Incheon, Republic of Korea.
  • Noh H; Celltrion Inc, Incheon, Republic of Korea.
  • Kim C; Celltrion Inc, Incheon, Republic of Korea.
  • Kim JI; Celltrion Inc, Incheon, Republic of Korea.
  • Kim M; Celltrion Inc, Incheon, Republic of Korea.
  • Ryu DK; Celltrion Inc, Incheon, Republic of Korea.
  • Lee MH; New Drug Development Center, Osong Medical Innovation Foundation, Cheongju, Republic of Korea.
  • Yang JS; Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of Korea.
  • Kim KC; Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of Korea.
  • Lee JY; Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of Korea.
  • Lee H; Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of Korea.
  • Woo HM; Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of Korea.
  • Kim JW; Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju, Republic of Korea.
  • Choi JA; Science Unit, International Vaccine Institute, Seoul, Republic of Korea.
  • Song M; Science Unit, International Vaccine Institute, Seoul, Republic of Korea.
  • Tomaszewska-Kiecana M; Biokinetica S.A. Phase 1 Unit, Jozefow, Poland.
  • Wolowik A; Biokinetica S.A. Phase 1 Unit, Jozefow, Poland.
  • Kulesza A; Biokinetica S.A. Phase 1 Unit, Jozefow, Poland.
  • Kim S; Celltrion Inc, Incheon, Republic of Korea.
  • Ahn K; Celltrion Inc, Incheon, Republic of Korea.
  • Jung N; Celltrion Inc, Incheon, Republic of Korea.
  • Lee SY; Celltrion Inc, Incheon, Republic of Korea.
Emerg Microbes Infect ; 11(1): 2315-2325, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36006772
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Clinical_trials Idioma: En Revista: Emerg Microbes Infect Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Clinical_trials Idioma: En Revista: Emerg Microbes Infect Año: 2022 Tipo del documento: Article